Three Fab Fragment Antibodies from Creative Biolabs Hit the Market

Posted by Jerry Carter on May 2nd, 2019

Creative Biolabs, an undisputed leader in recombinant antibody discovery and production, recently made three of its Fab fragment antibody products to the global market. The launch of the new products is expected to promote the research particularly about diseases such as refractory unstable angina, diabetic retinopathy, and psoriatic arthritis. On top of that, these antibodies can be applied to most of the immunological researches, as well. In some sense, this launch marks a giant step forward in the pharmaceutical industry.

A Fab fragment, which comprises four domains: V_H, CH1, V_L and CL1, contains 440-450 amino acids, with the molecular weight of approximately 47-48 kDa. Fab fragments enjoy noticeable advantages over full length antibodies. First of all, Fab fragment antibodies can easily penetrate tissues and be generated by some simpler expression systems, such as E. coli. Secondly, there exist no Fc regions in Fab fragments, thus making it impossible for interactions between Fc portions and Fc receptors. That’s why the Fab fragments can not only improve antibody specificity but also reduce the effector functions.

“Our company has been focusing on producing the best Fab fragment antibodies. We desire to offer a wide range of high-quality Fab fragment antibodies to our customers around the globe. This time, we succeed in launching three Fab fragment antibodies. I’m sure they will facilitate the research about related diseases, ultimately protecting human health. This is what we seek,” said a scientist from Creative Biolabs.

The products hitting the market include certolizumab pegol, ranibizumab, and abciximab. Certolizumab pegol is a recombinant antibody Fragment Fab to TNF alpha. It’s mainly used for the treatment of psoriatic arthritis. Basically, certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it’s a PEGylated Fab’ fragment of a humanized TNF inhibitor monoclonal antibody. Since polyethylene glycol does not cross the placenta, this antibody can be used even in pregnant women.

As a recombinant monoclonal antibody Fragment Fab to Human VEGF, ranibizumab is a monoclonal antibody fragment (Fab) derived from the same parent mouse antibody as bevacizumab. This antibody appears much smaller than its parent molecule. After affinity maturation, ranibizumab can provide stronger binding to VEGF-A. This monoclonal antibody can effectively treat diabetic retinopathy. Besides, it also can be applied to IP, IF, FuncS, FC, Neut, ELISA and IHC, etc.

Abciximab, a recombinant monoclonal antibody Fragment Fab to Human CD41, is a platelet aggregation inhibitor primarily used during and after coronary artery procedures (such as angioplasty) to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. To some extent, it functions as a glycoprotein IIb or IIIa inhibitor. This antibody can be used to treat refractory unstable angina in the case where percutaneous coronary intervention is planned.

Apart from these introduced products, quite a lot are still under research before they come into the market. By virtue of a team of extraordinary scientists, advanced technology and platforms, and its years of experience in the field, Creative Biolabs is making great contributions to the pharmacy field. The launch of the three antibodies is going to push forward the research about concerned diseases. On the other hand, it represents the pharmacy company’s promise to supply the optimal antibody products to all of its customers.

About Creative Biolabs

As a leader in recombinant antibody discovery and manufacturing, Creative Biolabs is committed to providing its global customers with the most comprehensive range of recombinant antibody products and extensive service portfolio at the most competitive price. Its products range from antibody/peptide libraries, biosimilar cell lines, chimeric antigen receptor (CDR) products, antibody-drug conjugates (ADC) to engineered antibodies. It also provides a variety of custom antibody discovery and engineering services.